Pressure is building and a breakout could be imminent.
It's taken 6 years from May 2013 where the high was 1816
Needs substantive news to make the push over the 1750s
Bear Trend Reversal - Long term downtrend rejected with bullish RSI divergence on the weekly.
These hops off a long-term bear trend reversals can be swift and powerful. I've played these before and won (DAN...TQQQ after '18 Christmas)..but I've also played these and lost (MAXR).
I've previously played these directly on the instrument, but this time I'm playing...
Still bullish on AZN.L but ascending broadening wedge :
- Need to break 7 580$ resistance
- RSI divergence
- MM20 > MM50
Statiscally in 80% of cases, the exit of this pattern is bearish.
So, I will open a short position around 7 400 $. (TPs on chart)
Always 2 gap to fill :
- Around 6 930 $
- Around 6 550 $
Happy trading
On October 18th, 2019, the FDA approved Amzeeq, otherwise known as FMX101 for the Israel based pharmaceutical company, Foamix. Amzeeq happens to be the first and only topical monocyline treatment to be used on acne patients. In anticipation of approval for this new product, shares of FOMX rallied from $2.53 per share on 10/08/2019 all the way up to highs around...
CVS Health Corporation is american stock pharmacy operator offering nice sell opportunities at new supply imbalances created on both the weekly and the monthly timeframes with everything pointing down in a clear downtrend with new supply levels being created and demand levels being eliminated. Strong imbalances created on the way down.Two new supply levels have...
Really like this chart & can see a good rise after MM's pull price down to support at 74.4p - also 200ma weekly at 72p
Best to scale in near the support level but watch out if RSI support level is not respected or 200ma as well, be ready to move out if so.
Long GBIO33 and Short HYPE3 on breakout from multiple timeframes negative trend line and GBIO33's strong bounce off lows. Fundamentally, HYPE3 well priced while GBIO33 is an undervalued growth case.
NVS Novartis owns or makes a slew of pharmacopial needs for a variety of medical needs.
Little dip during recent pullback.
Watching Friday ads, all brand names no companies. All Novartis or made for another company by Novartis.
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
BLRX had a strong rally today and it's just getting started.
In the related idea my price target was $1.34.
Today's high was $1.78
Check out the weekly chart:
Photo Finish.
$1.34 was 1.618 extension level from Waves 1 & 2.
Since the price-action broke $1.34 we will have an extended 3rd wave.
I expect a very strong rally tomorrow, I will update in the...
The price has closed above the downtrend line started this year with consistent volumes. I opened a buy as I am expecting increasing volume and strenght in the next sessions. Tps are already highlighted on the right.
